If 2025 felt like a year of preparation, 2026 is when the real changes arrive.

For medical device manufacturers operating across UK and European markets, the coming year brings a convergence of regulatory milestones that will fundamentally reshape how companies approach multilingual documentation.

From mandatory EUDAMED registration to the first EU MDR transition deadlines and the introduction of new UK pre-market requirements, 2026 demands strategic planning – particularly when it comes to medical device translation. Here’s our expert overview of what’s changing and what it means for your documentation strategy.

EUDAMED Goes Mandatory: 28 May 2026

Perhaps the most significant development for 2026 is the long-awaited mandatory implementation of EUDAMED. On 27 November 2025, the European Commission confirmed that the first four modules of the European database on medical devices are now fully functional, triggering a six-month transition period.

From 28 May 2026, the following modules become mandatory for both medical devices and IVDs:

• Actor registration (economic operators)
• UDI/Device registration database
• Notified Bodies and Certificates
• Market Surveillance

What This Means in Practice

This marks a fundamental shift: EUDAMED registration will become a prerequisite for placing new products on the EU market. All new devices, systems and procedure packs must be registered in EUDAMED before their first unit is placed on the market.

For devices already on the market before 28 May 2026, manufacturers have until 28 November 2026 to complete their EUDAMED registration – provided they continue marketing those devices.

Translation Implications

The mandatory EUDAMED requirements create several translation considerations:

• UDI consistency: Device identification data must be identical across all language versions of your documentation. Any discrepancy between your EUDAMED registration and translated materials could trigger compliance questions.
• Timeline integration: Translation must now be factored into product launch schedules earlier than ever. You cannot place a new device on the market without EUDAMED registration, so your translated documentation needs to be ready and aligned with your registration data.
• Public visibility: With certificate information becoming publicly accessible through EUDAMED, the quality of your documentation – including translated materials – becomes more visible to competitors, regulators and customers alike.

EU MDR Transition: The First Deadline Arrives

May 2026 also brings the first of the staggered EU MDR transition deadlines. While the extended transition periods have provided some breathing room, the clock is now firmly ticking.

Key Deadlines

• 26 May 2026: Class III custom-made implantable devices must achieve full MDR compliance. This is the first hard deadline with no further extensions available for this device category.
• 31 December 2027: All other Class III devices and Class IIb implantable devices (with some exceptions for well-established technologies).
• 31 December 2028: Class IIb (non-implantable), Class IIa, and Class I devices requiring notified body involvement.

The Bottleneck Warning

Industry analysts are warning of significant bottlenecks in 2026-2027. With Notified Bodies reporting average MDR certification review times of 13-18 months for standard devices (and longer for complex products), manufacturers who haven’t already engaged with their Notified Body risk certification gaps and potential market withdrawal.

This pressure extends to translation workflows. Technical documentation updates required for MDR compliance cascade through to all translated versions, and delays in translation can directly impact your certification timeline.

UK Pre-Market Requirements: What’s Coming

We covered the UK MDR changes in detail in our earlier blog post, but here’s a quick update on timing and any developments since then.

The UK’s new pre-market requirements are expected to come into force in early 2026, following the post-market surveillance regulations that took effect on 16 June 2025. The MHRA’s revised roadmap indicates draft regulations will be published on the WTO website mid-2025 for a mandatory 60-day consultation period, with the legislation expected to be introduced to Parliament late 2025. 

Key Changes to Prepare For

• Up-classification: Software as a Medical Device (SaMD) and implantable devices will face stricter requirements, resulting in expanded documentation packages.
• Implant cards: New requirements for patient-facing implant card documentation.
• UDI implementation: Mandatory unique device identifiers for certain device categories.
• International reliance framework: A new scheme recognising approvals from comparable regulators (Australia, Canada, EU, USA).
• Closer EU alignment: Many changes bring UK Essential Requirements closer to EU General Safety and Performance Requirements – though subtle differences will remain.

What This Means for Your Translation Strategy

The convergence of these regulatory milestones creates both challenges and opportunities for medical device manufacturers. Here’s how to approach translation planning for 2026:

1. Factor Translation Into Your Timeline Earlier

With EUDAMED registration required before market placement, translation can no longer be an afterthought. Build translation milestones into your product development schedule from the outset, not as a final step before launch.

2. Ensure Absolute Consistency

UDI data, device identifiers and technical specifications must be identical across all language versions. Work with translation partners who use robust terminology management systems and can guarantee consistency across your documentation portfolio.

3. Plan for Dual Compliance

If you’re selling in both UK and EU markets, you’ll need to navigate two regulatory frameworks that are aligning in some areas but diverging in others. This may require market-specific documentation versions, with translation workflows that can handle these nuances efficiently.

4. Budget for Increased Documentation Volumes

Up-classification means more comprehensive technical files. More documentation means more translation. Review your translation budgets now and consider how Translation Memory technology can help manage costs as volumes increase.

5. Don’t Overlook Patient-Facing Materials

New requirements for implant cards and patient information demand a different translation approach – one that prioritises clarity and cultural sensitivity over technical precision. These materials require localisation expertise, not just linguistic accuracy.

6. Build in Contingency

With Notified Body bottlenecks expected, certification timelines may slip. Ensure your translation workflows are flexible enough to accommodate last-minute documentation changes without derailing your market access plans.

You can use our online MDR Translation Checklist to help your planning and keep you on track.

Looking Ahead: Potential MDR/IVDR Simplification

It’s worth noting that the European Commission is actively working on proposals to simplify MDR and IVDR. Following calls from the European Parliament and industry stakeholders, targeted amendments are expected that could provide relief for orphan devices and breakthrough technologies, whilst improving governance and system efficiency.

We’ll be monitoring these developments closely and will update our guidance as the regulatory landscape evolves.

Key Takeaways

1. 26 May 2026: First EU MDR transition deadline for Class III custom-made implantable devices.
2. 28 May 2026: EUDAMED becomes mandatory – registration required before placing new devices on the EU market.
3. Early 2026: UK pre-market requirements expected to come into force.
4. Translation volumes will increase due to up-classification and expanded documentation requirements.
5. Timeline integration is critical: translation must be built into product launch schedules from the start.
6. Consistency across languages becomes more important than ever with mandatory EUDAMED registration.
7. Dual UK/EU compliance requires strategic planning for manufacturers operating across both markets.

How Omnilingua Can Help

For over 25 years, we’ve been helping medical device manufacturers navigate regulatory complexity. Our deep understanding of both UK and EU requirements, combined with advanced Translation Memory technology and specialist expertise in medical and technical documentation, makes us the ideal partner as you prepare for the changes ahead.

Whether you need support with IVDR documentation, MDR transition projects, or strategic translation planning for 2026 and beyond, get in contact, we’re here to help.

This article provides general guidance based on publicly available information about current and proposed regulations. For specific compliance advice, consult with qualified regulatory professionals.